All the news Showing 10 of 18 articles from: Russian FederationGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Access to medicines & diagnostics Russia struggling with adequate access to hepatitis C drugs Pharma Letter / 25 October 2021 Hepatitis D Myrcludex B plus tenofovir suppresses hepatitis delta Liz Highleyman / 30 April 2018 An experimental drug that blocks the entry of hepatitis B virus (HBV) and hepatitis delta virus (HDV) into liver cells suppressed HBV and HDV levels and led to improvement in ... Treatment outcomes Real-world studies show 8-week sofosbuvir/ledipasvir course just as effective as 12-week course for genotype 1 patients without cirrhosis Keith Alcorn / 02 December 2016 An 8-week course of treatment with sofosbuvir/ledipasvir is just as effective as a 12-week course of treatment in people without cirrhosis, including those with HIV/hepatitis C virus (HCV) co-infection, and could significantly reduce ... Access to medicines & diagnostics Buyers clubs for cheaper drugs help fight hepatitis and HIV Reuters / 07 November 2016 Access to medicines & diagnostics Generic hepatitis C drugs purchased online achieve high cure rates Keith Alcorn / 27 October 2016 Use of generic versions of direct-acting antivirals resulted in very high cure rates for people who obtained the products through three buyers’ clubs, indicating that the generic products are effective, according to three ... Drug dependence treatment How three drug users took on the might of the Russian state The Guardian / 15 September 2016 Harm reduction interventions and policy While Russia grapples with HIV epidemic, Moscow's addicts share their filthy needles The Guardian / 26 May 2015 Finance, funding & health economics Russia's harm reduction programs threatened by want of funds Manual Items / 25 September 2014 Harm reduction interventions and policy Report: Substitution maintenance treatment in Ukraine: Humanitarian and medical mission EATG / 23 June 2014 Hepatitis delta Prolonged pegylated interferon plus tenofovir does not prevent hepatitis delta relapse Liz Highleyman / 23 April 2014 Treating hepatitis B patients with hepatitis delta virus (HDV) co-infection using pegylated interferon plus tenofovir (Viread) for 96 weeks may reduce HDV viral load, but side-effects are frequent and it did not significantly improve ... ← First12Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive